Treatment Experienced: Suppressed, Ol's, Prophylaxis, & Tx


A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intesification or Intesification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

A5332: REPRIEVE - Randomized Trial to Prevent Vascular Events in HIV

A5345: Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause (IMAP)

A5360:  Minimal Versus Standard Monitoring for the Delivery of All Oral Ribavirin-Free Pan Genotypic Directly Acting Antivirals to Chronically Infected Treatment Naïve HCV Populations Globally: MINMON Study

CID 0819:  Apheresis Procedures to Obtain Leukocytes from HIV+ Subjects

CID 0819:  Single Sample and Short Term Longitudinal Sample Collection

CID 0819:  Serial Blood Sample Collection

IGHD 11424 - The VOR VAX Study: The Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

 IGHID 11627 - XTRA Study: A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T-Cell Therapy (HXTC) on Persistent HIV-1 Infection HIV-Infected Individuals Started on Antiretroviral Therapy

20, HIV-1 infected patients > 18 years of age with undetectable viral load and CD4 count > 300; no known cardiac hx or known resistance to ≥ 2 classes of drugs.